Post-earnings recap
Reported
Mon, May 4, 2026
EPS actual
$0.76
EPS est.
$0.78
EPS surprise
-2.44%
1-day move
+2.59%
BioMarin's earnings report showed a miss on EPS compared to expectations, which could raise concerns among investors. However, the stock reacted positively, increasing by 2.59%. This increase may reflect investor optimism despite the earnings miss, possibly due to other underlying factors not detailed in the earnings call.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.76 | $0.97 | -2.44% |
| Revenue | N/A | $754M | N/A |
No transcript is on record, and the analysis is based on numerical results only.
BioMarin Pharmaceutical Inc. is a biotechnology company focused on developing and commercializing innovative biopharmaceuticals for serious diseases and medical conditions. Operating in the health care sector, BioMarin is particularly known for its treatments for rare genetic disorders, making it a key player in the biotechnology industry.
Last quarter
In Q4 2025, BioMarin reported an EPS of $0.46, significantly exceeding expectations. However, the stock saw a decline of 1.81% the following day, indicating market skepticism despite the positive earnings surprise.
EPS beat streak
1Q
EPS beat rate
75%
Avg EPS surprise
+104.31%
Avg 1-day reaction
+0.39%
Analysts expect BioMarin to report solid earnings this quarter, with a consensus EPS of $0.97. The market is closely watching how the company performs against these expectations, especially given its mixed earnings history.
Bull case
If BioMarin can meet or exceed the EPS estimate, it could signal strong demand for its products and boost investor confidence, potentially leading to a positive stock reaction.
Bear case
Conversely, if the company misses earnings expectations, it could raise concerns about its growth prospects and lead to a significant drop in the stock price.
Key metrics to watch
EPS
$0.97Earnings per share is a crucial indicator of the company's profitability and financial health.
Revenue
$754MRevenue figures will provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will BioMarin achieve an EPS of $0.97 or higher?
This figure is critical as it will determine whether the company meets market expectations and influences investor sentiment.
Q2
What are the revenue figures compared to the consensus of $754M?
Revenue performance will provide insights into the demand for BioMarin's products and its overall market position.
—
Est. EPS
$0.01
Est. Rev
$918M
Impl. Move
±9.1%
Why consensus could be wrong
The Street may be underestimating the potential for BioMarin to exceed EPS expectations due to recent product launches that have not been fully accounted for.
Supporting evidence
The company has a strong history of beating EPS estimates, with an 88% success rate over the last eight quarters.
Recent product performance suggests higher sales than analysts anticipate, particularly in the rare disease segment.
Key risk
If revenue comes in below $700M, it could undermine the bullish sentiment surrounding the stock.
Pre-commit to what would confirm each case.
The market is debating whether BioMarin can sustain its growth amid competitive pressures and evolving market conditions.
Bull confirmed if
An EPS of $1.00 or higher would confirm strong demand and operational efficiency.
Bear confirmed if
An EPS below $0.74 would raise concerns about the company's growth trajectory.
What the market is pricing for the move.
Implied Move
±9.06%
Historical Avg
±2.1%
The options market is pricing in a significant move for BioMarin's stock, indicating that traders expect volatility around the earnings report.
Options are pricing ±9.1% while BMRN has averaged ±2.1% over the last 8 prints — setup is pricing rich.
ATM IV
0.6%
30d HV
25.6%
Smart-money positioning from the most recent 13F filings.
Institutional
103.53%
of float
Insider
0.34%
of float
Holders
757
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
20,445,212 sh · $1.1B
10.56%
3.2%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If BioMarin beats expectations, history suggests the stock could rise by around 3.73%, confirming strong market demand.
In line / cautious
If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.
Miss
A miss could lead to a decline of approximately 3.32%, reflecting investor disappointment and concerns about future growth.
The lines on the call that would change the story.
Dodge & Cox Inc.
14,844,930 sh · $819.4M
7.67%
1.9%
Primecap Management Company
14,190,183 sh · $783.3M
7.33%
-0.0%
Vanguard Capital Management LLC
8,743,633 sh · $482.6M
4.52%
1.2%
Vanguard Portfolio Management LLC
8,648,678 sh · $477.4M
4.47%
4.2%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.